Company Overview - Genmab A/S is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics [2][3] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [3] Product Pipeline and Vision - Genmab has developed a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function-enhanced antibodies [2] - The company's vision by 2030 is to transform the lives of patients with cancer and other serious diseases through its "knock-your-socks-off" (KYSO) antibody medicines [2] Upcoming Events - Genmab's Chief Financial Officer, Anthony Pagano, will participate in a fireside chat at the 46th Goldman Sachs Annual Global Healthcare Conference on June 9, 2025 [1]

Biomarker analysis from Phase 3 ARMOR study reveals significant reduction in inflammation, cardiac stress, and atherosclerotic drivers, unlocking potential new commercial and clinical pathways. Validated decrease in ANP (Atrial Natriuretic Peptide), a key clinical marker for heart failure, highlights expansion potential into broader cardiometabolic markets. Strategic collaboration with Proteas Health positions Galmed at the forefront of AI-driven biomarker-guided therapeutics.TEL AVIV, Israel, May 27, 2025 ...

The Company plans to submit a Phase 2 trial protocol for SER-155 in allo-HSCT to the FDA in the coming weeks and is actively seeking partners to support continued clinical development. Presentation Details Results highlight potential role of SER-155 in promoting peripheral T-cell recovery and immune reconstitution to support favorable outcomes post allogeneic hematopoietic stem cell transplant (allo-HSCT) CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or th ...

Core Viewpoint - Plus Therapeutics, Inc. has received a delinquency notification from Nasdaq due to the delayed filing of its Quarterly Report for the period ended March 31, 2025, but this does not immediately affect its listing status on Nasdaq [1][2]. Group 1: Compliance and Filing Status - The Company must submit a plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) by July 21, 2025 [2]. - If the compliance plan is accepted, Nasdaq may grant an extension of up to 180 calendar days, allowing the Company until November 17, 2025, to regain compliance [2]. - The Company is actively working to file the Quarterly Report as soon as possible and aims to return to a normal filing schedule for the remainder of 2025 [2]. Group 2: Company Overview - Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for challenging cancers of the central nervous system [3]. - The Company employs a combination of image-guided local beta radiation and targeted drug delivery methods, with key programs targeting leptomeningeal metastases and recurrent glioblastoma [3]. - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [3].

Core Insights - DuPont de Nemours, Inc. (DD) has launched AmberChrom TQ1 chromatography resin aimed at purifying oligonucleotides and peptides for biopharma applications, enhancing its product portfolio and establishing a new benchmark in the industry [1][2][3] Group 1: Product Launch and Features - The AmberChrom TQ1 chromatography resin is an agarose-based product that offers higher loading capacity, increased throughput, and lower pressure requirements compared to competing products, making it suitable for high-resolution separations and large-scale purifications [2] - The resin is designed to work in conjunction with existing AmberChrom XT and CG chromatography resins, facilitating the purification of various oligonucleotide feeds and aiding in the crude purification of peptide feeds [3] Group 2: Performance Validation - DuPont has published internal application studies using real-world drug feeds to validate the performance characteristics of the AmberChrom TQ1 resin, supporting its integration into processes from drug discovery to commercialization [3] Group 3: Financial Outlook - For the second quarter, DuPont projects net sales of approximately $3.2 billion, operating EBITDA of around $815 million, and adjusted earnings per share of about $1.05, reflecting a seasonal increase in sales [6] - The company has maintained its full-year 2025 guidance, indicating confidence in its financial performance moving forward [6] Group 4: Stock Performance - DuPont's stock has experienced a decline of 14.5% over the past year, which is less severe compared to the industry's overall decline of 26.6% [5]

Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020 NEW YORK and WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune disea ...

Tivic Health Systems (TIVC) Conference Summary Company Overview - Tivic Health Systems is undergoing a significant transformation, shifting from a single product over-the-counter device company to a diversified immunotherapeutics company focused on immunotherapeutic applications and bioelectronic programs [3][4][31]. Core Business Developments - The company has licensed a phase three immunotherapy program, specifically a TLR five agonist, which includes two molecules and over 40 clinical trials, with a focus on acute radiation syndrome and additional indications in oncology and longevity [5][6][9]. - The TLR five program has received significant investment, totaling over $140 million, and has garnered interest from government agencies for its potential applications in emergency situations related to radiation exposure [10][11]. Product Pipeline and Market Potential - **Acute Radiation Syndrome (ARS)**: The TLR five drug, entolimod, has shown a threefold increase in survival rates in clinical trials and is on a fast track for FDA approval. The company is exploring emergency use designations to expedite market entry [12][15]. - **Neutropenia Market**: The market for neutropenia treatments is projected to exceed $20 billion by 2032, with TLR five drugs positioned to capture significant market share [17][20]. - **Vagus Nerve Stimulation (VNS)**: Tivic is developing a noninvasive VNS device, which has shown promising results in clinical trials, including a 60% decrease in gamma waves and a 2x increase in heart rate variability [21][23]. Strategic Positioning - The company is strategically positioned to leverage its dual approach of biologics and bioelectronic therapies to address immune system dysfunction across various diseases [7][8][31]. - Tivic Health aims to differentiate itself from competitors by offering noninvasive alternatives to existing implanted technologies, potentially expanding market access [25][27]. Financial and Operational Insights - The company has resolved previous Nasdaq deficiencies and currently has no debt, with a stable trading volume and a well-structured cap table [29][30]. - Recent financing efforts have provided sufficient capital to sustain operations for the next 12 to 18 months [44][45]. Distribution and Revenue Generation - The distribution strategy for the TLR five product will focus on government sales, requiring a limited sales team and leveraging existing consultant relationships [32][33]. - Revenue generation timelines are contingent on emergency use designations, with potential revenue starting within 12 to 18 months [34]. Challenges and Considerations - The company acknowledges the competitive landscape in the depression treatment market, which is heavily defended by pharmaceutical companies, and anticipates a complex regulatory pathway for its VNS device [36][38]. - The over-the-counter product line is currently breakeven, and the company is considering strategic alternatives for this segment [46][48]. Conclusion - Tivic Health Systems is positioned for growth through its innovative immunotherapeutic and bioelectronic product offerings, with a focus on addressing significant market needs in radiation exposure and immune system disorders. The company is actively pursuing regulatory pathways and strategic partnerships to enhance its market presence and financial stability [31][59].

JENA, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will participate in multiple investor conferences in June and July 2025. Jefferies Global Healthcare ConferenceJune 3 - 5, 2025 in New York, NY InflaRx will conduct an investor presentation on June 4th at 7:35 AM ET and will participate in one-on-one investor meetings. A link to register for the ...

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will participate in the following upcoming healthcare conferences: Investment Conferences Jefferies Global Healthcare Conference (New York)   Presentation Thursday, June 5, 9:20 AM ET + 1x1 meetings Sachs European BioPharma Obesity Innovation Forum   Next Gen Th ...

Armata Pharmaceuticals (ARMP) shares have skyrocketed 72.3% in the past month. The massive surge in the stock price was observed after the company announced positive top-line results from its early to mid-stage study evaluating its pipeline candidate, AP-SA02, for the treatment of Staphylococcus aureus bacteremia (SAB), earlier this week. AP-SA02 is ARMP’s novel intravenously administered multi-phage therapeutic.The phase Ib/IIa diSArm multiple ascending dose escalation study is assessing the safety, tolera ...